EUROPEAN NEUROPSYCHOPHARMACOLOGY

metrics 2024

Exploring Innovations in Neuropsychopharmacology

Introduction

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

Metrics 2024

SCIMAGO Journal Rank1.76
Journal Impact Factor6.10
Journal Impact Factor (5 years)5.30
H-Index130
Journal IF Without Self6.10
Eigen Factor0.01
Normal Eigen Factor1.92
Influence1.74
Immediacy Index2.00
Cited Half Life7.60
Citing Half Life7.30
JCI1.27
Total Documents3104
WOS Total Citations8533
SCIMAGO Total Citations36218
SCIMAGO SELF Citations1069
Scopus Journal Rank1.76
Cites / Document (2 Years)4.22
Cites / Document (3 Years)4.52
Cites / Document (4 Years)4.52

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #17/272
Percentile 93.75
Quartile Q1
Psychiatry and Mental Health in Medicine
Rank #47/567
Percentile 91.71
Quartile Q1
Neurology in Neuroscience
Rank #18/192
Percentile 90.62
Quartile Q1
Neurology (clinical) in Medicine
Rank #37/400
Percentile 90.75
Quartile Q1
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #33/313
Percentile 89.46
Quartile Q1
Biological Psychiatry in Neuroscience
Rank #8/51
Percentile 84.31
Quartile Q1

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 22/277
Percentile 92.20
Quartile Q1
NEUROSCIENCES
Rank 33/310
Percentile 89.50
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 26/354
Percentile 92.80
Quartile Q1
PSYCHIATRY
Rank 21/276
Percentile 92.60
Quartile Q1

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 49/278
Percentile 82.37
Quartile Q1
NEUROSCIENCES
Rank 61/310
Percentile 80.32
Quartile Q1
PHARMACOLOGY & PHARMACY
Rank 46/354
Percentile 87.01
Quartile Q1
PSYCHIATRY
Rank 45/276
Percentile 83.70
Quartile Q1

Quartile History

Similar Journals

Translational Psychiatry

Bridging science and practice for a healthier mind.
Publisher: SPRINGERNATUREISSN: 2158-3188Frequency: 1 issue/year

Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

Brain Communications

Exploring the Frontiers of Brain Research
Publisher: OXFORD UNIV PRESSISSN: Frequency: 1 issue/year

Brain Communications is an esteemed, open-access academic journal published by Oxford University Press since 2019, focusing on the dynamic field of neuroscience. With a dedicated ISSN and an E-ISSN of 2632-1297, this journal aims to address the intricate relationships between brain functions, psychiatric disorders, and neurobiological mechanisms. The journal stands out in the academic realm, holding a prestigious Q1 ranking across several categories, including Biological Psychiatry, Cellular and Molecular Neuroscience, Neurology, and Psychiatry and Mental Health for 2023. Notably, it has also secured impressive Scopus ranks in various neuroscience and psychiatry fields, evidencing its commitment to high-quality research. With an impact factor reflective of its growing influence, Brain Communications provides accessible research findings to professionals, researchers, and students alike, fostering a deeper understanding of complex neurological phenomena. This innovative journal is pivotal for anyone involved in advancing knowledge in neuroscience and mental health.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Pioneering Research for Tomorrow's Therapeutics
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0278-5846Frequency: 8 issues/year

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

MOLECULAR PSYCHIATRY

Transforming Understanding of Psychiatric Disorders through Molecular Research
Publisher: SPRINGERNATUREISSN: 1359-4184Frequency: 12 issues/year

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

NeuroImage-Clinical

Transforming Clinical Practice through Cutting-edge Research
Publisher: ELSEVIER SCI LTDISSN: 2213-1582Frequency:

NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.

CORTEX

Connecting Minds: Where Neuroscience Meets Innovation
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0010-9452Frequency: 10 issues/year

CORTEX is a premier international journal published by Elsevier Masson, focusing on the cutting-edge areas of cognitive neuroscience, psychology, and neurology. With an impressive impact factor that places it in Q1 quartiles across multiple categories such as Cognitive Neuroscience and Neuropsychology, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 1964, CORTEX has continued to excel in disseminating high-quality scholarly work, offering insights that significantly enhance our understanding of the brain's functioning and behavior. Although not an open-access publication, it provides various access options to ensure the dissemination of knowledge is as wide-reaching as possible. As the field of cognitive psychology evolves, CORTEX remains at the forefront, fostering an environment for interdisciplinary collaboration and innovation. Researchers seeking to stay engaged with the latest advancements will find CORTEX an indispensable tool for their professional development.

Neuropsychopharmacology Reports

Illuminating the complexities of neuropsychopharmacology for a healthier future.
Publisher: WILEYISSN: Frequency: 4 issues/year

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Advancing Understanding in Biological Psychiatry.
Publisher: TAYLOR & FRANCIS LTDISSN: 1562-2975Frequency: 8 issues/year

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Connecting global minds in pharmacology and psychiatry.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

Noropsikiyatri Arsivi-Archives of Neuropsychiatry

Fostering Interdisciplinary Approaches to Mental Health
Publisher: TURKISH NEUROPSYCHIATRY ASSOC-TURK NOROPSIKIYATRI DERNEGIISSN: 1300-0667Frequency: 4 issues/year

Noropsikiyatri Arsivi-Archives of Neuropsychiatry is a prominent scholarly journal dedicated to advancing knowledge in the fields of neuropsychiatry and mental health. Published by the Turkish Neuropsychiatry Association, this journal aims to disseminate high-quality research that contributes to a deeper understanding of psychiatric disorders, innovative treatment modalities, and interdisciplinary approaches in neuroscience. Based in Turkey, the journal has been in circulation since its inception, with a rich history reflecting its commitment to addressing contemporary issues in mental health care. It is currently indexed under Scopus, with notable rankings in both Psychiatry and Mental Health (Rank #378/567, 33rd Percentile) and General Neuroscience (Rank #97/113, 14th Percentile), highlighting its increasing relevance and impact in the academia. Although it is not currently an open access journal, its contributions remain vital for researchers, professionals, and students who wish to stay abreast of the latest developments and research in neuropsychiatry.